Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1270-1279

  Uchiyama, Toru ^a,b   Adriani, Marsilio ^a,c   Jagadeesh, G Jayashree ^a   Paine, Adam ^a   Candotti, Fabio ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FOAMY VIRUS VECTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; WISKOTT ALDRICH SYNDROME PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; T LYMPHOCYTE; TARGETED GENE REPAIR; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; VIRAL GENE DELIVERY SYSTEM; WISKOTT ALDRICH SYNDROME;

ANIMALIA; HUMAN SPUMARETROVIRUS; MUS;

EID: 84861913473     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.282     Document Type: Article

References (49)

1. Ochs, HD and Thrasher, AJ (2006). The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117: 725-38; quiz 739.
2. Derry, JM, Ochs, HD and Francke, U (1994). Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78: 635-644. (Pubitemid 24268586)
3. Thrasher, AJ (2002). WASp in immune-system organization and function. Nat Rev Immunol 2: 635-646.
4. Ozsahin, H, Cavazzana-Calvo, M, Notarangelo, LD, Schulz, A, Thrasher, AJ, Mazzolari, E et al. (2008). Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 111: 439-445.
5. Klein, C, Nguyen, D, Liu, CH, Mizoguchi, A, Bhan, AK, Miki, H et al. (2003). Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 101: 2159-2166. (Pubitemid 36302053)
6. Strom, TS, Turner, SJ, Andreansky, S, Liu, H, Doherty, PC, Srivastava, DK et al. (2003). Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood 102: 3108-3116. (Pubitemid 37314745)
7. Dupré, L, Marangoni, F, Scaramuzza, S, Trifari, S, Hernández, RJ, Aiuti, A et al. (2006). Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 17: 303-313.
8. Charrier, S, Dupré, L, Scaramuzza, S, Jeanson-Leh, L, Blundell, MP, Danos, O et al. (2007). Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 14: 415-428.
9. Bosticardo, M, Marangoni, F, Aiuti, A, Villa, A and Grazia Roncarolo, M (2009). Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 113: 6288-6295.
10. Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
11. Heneine, W, Schweizer, M, Sandstrom, P and Folks, T (2003). Human infection with foamy viruses. Curr Top Microbiol Immunol 277: 181-196. (Pubitemid 36612746)
12. Falcone, V, Schweizer, M and Neumann-Haefelin, D (2003). Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol 277: 161-180. (Pubitemid 36612745)
13. Vassilopoulos, G, Trobridge, G, Josephson, NC and Russell, DW (2001). Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 98: 604-609.
14. Josephson, NC, Trobridge, G and Russell, DW (2004). Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors. Hum Gene Ther 15: 87-92. (Pubitemid 38147191)
15. Josephson, NC, Vassilopoulos, G, Trobridge, GD, Priestley, GV, Wood, BL, Papayannopoulou, T et al. (2002). Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 99: 8295-8300. (Pubitemid 34651046)
16. Leurs, C, Jansen, M, Pollok, KE, Heinkelein, M, Schmidt, M, Wissler, M et al. (2003). Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther 14: 509-519. (Pubitemid 36442706)
17. Bauer, TR Jr, Allen, JM, Hai, M, Tuschong, LM, Khan, IF, Olson, EM et al. (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 14: 93-97.
18. Kiem, HP, Allen, J, Trobridge, G, Olson, E, Keyser, K, Peterson, L et al. (2007). Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 109: 65-70. (Pubitemid 46053045)
19. Si, Y, Pulliam, AC, Linka, Y, Ciccone, S, Leurs, C, Yuan, J et al. (2008). Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. Blood 112: 4458-4465.
20. Trobridge, GD, Miller, DG, Jacobs, MA, Allen, JM, Kiem, HP, Kaul, R et al. (2006). Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103: 1498-1503. (Pubitemid 43191194)
21. Zhang, F, Thornhill, SI, Howe, SJ, Ulaganathan, M, Schambach, A, Sinclair, J et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110: 1448-1457. (Pubitemid 47443959)
22. Dupré, L, Aiuti, A, Trifari, S, Martino, S, Saracco, P, Bordignon, C et al. (2002). Wiskott- Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity 17: 157-166. (Pubitemid 35245958)
23. Snapper, SB, Rosen, FS, Mizoguchi, E, Cohen, P, Khan, W, Liu, CH et al. (1998). Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9: 81-91. (Pubitemid 28361297)
24. Zhang, J, Shehabeldin, A, da Cruz, LA, Butler, J, Somani, AK, McGavin, M et al. (1999). Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med 190: 1329-1342.
25. Westerberg, L, Larsson, M, Hardy, SJ, Fernández, C, Thrasher, AJ and Severinson, E (2005). Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood 105: 1144-1152. (Pubitemid 40170887)
26. Snapper, SB, Meelu, P, Nguyen, D, Stockton, BM, Bozza, P, Alt, FW et al. (2005). WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J Leukoc Biol 77: 993-998. (Pubitemid 40770852)
27. Tsuboi, S, Nonoyama, S and Ochs, HD (2006). Wiskott-Aldrich syndrome protein is involved in αIIb β3-mediated cell adhesion. EMBO Rep 7: 506-511. (Pubitemid 43904867)
28. Linder, S, Nelson, D, Weiss, M and Aepfelbacher, M (1999). Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc Natl Acad Sci USA 96: 9648-9653. (Pubitemid 29398786)
29. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751. (Pubitemid 36712571)
30. Moebes, A, Enssle, J, Bieniasz, PD, Heinkelein, M, Lindemann, D, Bock, M et al. (1997). Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 71: 7305-7311. (Pubitemid 27391668)
31. Yu, SF, Baldwin, DN, Gwynn, SR, Yendapalli, S and Linial, ML (1996). Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 271: 1579-1582. (Pubitemid 26097215)
32. Trobridge, G and Russell, DW (2004). Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 78: 2327-2335. (Pubitemid 38228926)
33. Mantovani, J, Charrier, S, Eckenberg, R, Saurin, W, Danos, O, Perea, J et al. (2009). Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J Gene Med 11: 645-654.
34. Mucenski, ML, Taylor, BA, Ihle, JN, Hartley, JW, Morse, HC 3rd, Jenkins, NA et al. (1988). Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8: 301-308. (Pubitemid 18015584)
35. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174. (Pubitemid 40696434)
36. Westerberg, LS, de la Fuente, MA, Wermeling, F, Ochs, HD, Karlsson, MC, Snapper, SB et al. (2008). WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 112: 4139-4147.
37. Meyer-Bahlburg, A, Becker-Herman, S, Humblet-Baron, S, Khim, S, Weber, M, Bouma, G et al. (2008). Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood 112: 4158-4169.
38. Konno, A, Wada, T, Schurman, SH, Garabedian, EK, Kirby, M, Anderson, SM et al. (2004). Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood 103: 676-678. (Pubitemid 38140104)
39. Charrier, S, Stockholm, D, Seye, K, Opolon, P, Taveau, M, Gross, DA et al. (2005). A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 12: 597-606. (Pubitemid 40468107)
40. Blundell, MP, Bouma, G, Calle, Y, Jones, GE, Kinnon, C and Thrasher, AJ (2008). Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy. Mol Ther 16: 836-844. (Pubitemid 351587092)
41. Marangoni, F, Bosticardo, M, Charrier, S, Draghici, E, Locci, M, Scaramuzza, S et al. (2009). Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther 17: 1073-1082.
42. Zanta-Boussif, MA, Charrier, S, Brice-Ouzet, A, Martin, S, Opolon, P, Thrasher, AJ et al. (2009). Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther 16: 605-619.
43. Martín, F, Toscano, MG, Blundell, M, Frecha, C, Srivastava, GK, Santamaría, M et al. (2005). Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 12: 715-723. (Pubitemid 40561509)
44. Williams, S, Mustoe, T, Mulcahy, T, Griffiths, M, Simpson, D, Antoniou, M et al. (2005). CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 5: 17.
45. Antoniou, M, Harland, L, Mustoe, T, Williams, S, Holdstock, J, Yague, E et al. (2003). Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 82: 269-279. (Pubitemid 36952300)
46. Bosticardo, M, Draghici, E, Schena, F, Sauer, AV, Fontana, E, Castiello, MC et al. (2011). Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol 127: 1376-84.e5.
47. Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J and Russell, DW (2002). Improved foamy virus vectors with minimal viral sequences. Mol Ther 6: 321-328. (Pubitemid 36305333)
48. Wada, T, Jagadeesh, GJ, Nelson, DL and Candotti, F (2002). Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther 13: 1039-1046. (Pubitemid 34717850)
49. McCarty, OJ, Larson, MK, Auger, JM, Kalia, N, Atkinson, BT, Pearce, AC et al. (2005). Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem 280: 39474-39484. (Pubitemid 41713905)